Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment ...

Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not ...

Oncologists share their treatment preferences for patients with advanced NSCLC with EGFR mutations. Improving survival and ...

EGFR inhibitors such as Erbitux and Gilotrif show potential in laboratory and mouse studies in treating melanoma with a ...

Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress Continued progress in advancing varoglutamstat in kidney disease based on encouraging data and expansion of IP ...

The Scorpion Therapeutics spinoff sold rights for two EGFR inhibitors to Pierre Fabre Laboratories and is hoping to become a clinical-stage firm by 2026.

SGLT2 inhibitors have been shown to reduce risk of acute kidney injury, but whether kidney effects are modified by risk of acute dips in eGFR is unknown.

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events ...

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.